Fragment based search for small molecule inhibitors of HIV-1 Tat-TAR
摘要:
Basic molecular building blocks such as benzene rings, amidines, guanidines, and amino groups have been combined in a systematic way to generate ligand candidates for HIV-1 TAR RNA. Ranking of the resulting compounds was achieved in a fluorimetric Tat-TAR competition assay. Although simple molecules such as phenylguanidine are inactive, few iteration steps led to a set of ligands with IC50 values ranging from 40 to 150 mu M. 1,7-Diaminoisoquinoline 17 and 2,4,6-triaminoquinazoline 22 have been further characterized by NMR titrations with TAR RNA. Compound 22 is bound to TAR at two high affinity sites and shows slow exchange between the free ligand and the RNA complex. These results encourage investigations of dimeric ligands built from two copies of compound 22 or related heterocycles. (C) 2014 Elsevier Ltd. All rights reserved.
[EN] NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF ß-SECRETASE (BACE)<br/>[FR] NOUVEAUX DERIVES DE 2-AMINO-QUINAZOLINE UTILES EN TANT QU'INHIBITEURS DE LA $G(B)-SECRETASE (BACE)
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2006017844A1
公开(公告)日:2006-02-16
The present invention is directed to novel 2-amino-3,4-dihydro-quinazoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer’s disease (AD) and related disorders. The compounds of the invention are inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE.
[EN] 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF B-SECRETASE (BACE)<br/>[FR] DERIVES DE 2-AMINO-QUINAZOLINE UTILES EN TANT QU'INHIBITEURS DE B-SECRETASE (BACE)
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2006024932A1
公开(公告)日:2006-03-09
The present invention is directed to novel 2-amino-3,4-dihydroquinazoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of ß-secretase, also known as ß-site cleaving enzyme and BACE.
HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS
申请人:Amberg Wilhelm
公开号:US20100041698A1
公开(公告)日:2010-02-18
The invention relates to compounds of general formula (I), corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof and the prodrugs of said compounds. The invention also relates to the use of said compounds as binding partners for 5-HT5 receptors for treating diseases that are modulated by a 5-HT5 receptor activity, in particular, for treating neurodegenerative and neuropsychiatric disorders as well as signs, symptoms and dysfunctions.
2-aminoarylmethylamine solid support templated for preparation of highly functionalized heterocycle compounds
申请人:——
公开号:US20020032262A1
公开(公告)日:2002-03-14
A solid support template for the preparation of highly functionalized heterocycle compounds of the formula;
1
一种固体支撑模板,用于制备公式为1的高度功能化杂环化合物。
Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE)
申请人:Bischoff Paul Francois
公开号:US20060178383A1
公开(公告)日:2006-08-10
The present invention is directed to novel 2-amino-3,4-dihydro-quinazoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE.